SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Oddis CV, Conte CG, Steen VD, Medsger TA Jr. Incidence of polymyositis-dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982. J Rheumatol 1990; 17: 132934.
  • 2
    Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA 2011; 305: 18390.
  • 3
    Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 257281.
  • 4
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 22132.
  • 5
    Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al, for the Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol 2011; 38: 143640.
  • 6
    Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 2005; 52: 6017.
  • 7
    Mahler EA, Blom B, Voermans NC, van Engelen BG, van Riel PL, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford) 2011; 50: 220613.
  • 8
    Rios Fernandez R. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies: a report of 4 cases and review of the literature. Clin Exp Rheumatol 2009; 27: 100916.
  • 9
    Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti–signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62: 132834.
  • 10
    Chiu YE, Co DO. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use [published erratum appears in Pediatr Dermatol 2011;28:627]. Pediatr Dermatol 2011; 28: 35767.
  • 11
    Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 228190.
  • 12
    Rider LG, Giannini EH, Harris-Love M, Galen J, Isenberg D, Pilkington CA, et al. Defining clinical improvement in adult and juvenile myositis. J Rheumatol 2003; 30: 60317.
  • 13
    Sultan SM, Allen E, Oddis CV, Kiely P, Cooper RG, Lundberg IE, et al. Reliability and validity of the Myositis Disease Activity Assessment Tool. Arthritis Rheum 2008; 58: 35939.
  • 14
    D'Agostino RB Sr. The delayed-start study design. N Engl J Med 2009; 361: 13046.
  • 15
    Feldman BM, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001; 54: 5507.
  • 16
    Bohan A, Peter JB, Bowman RL, Pearson CM. A computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 1977; 56: 25586.
  • 17
    Van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooj WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61: 31621.
  • 18
    Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62: 46572.
  • 19
    Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 126273.
  • 20
    Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 13745.
  • 21
    Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 17619.
  • 22
    Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002; 28: 85990, viii.
  • 23
    Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, et al, for the Childhood Myositis Heterogeneity and International Myositis Collaborative Study Groups. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54: 36829.
  • 24
    Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36: 254751.
  • 25
    Gunawardena H, Wedderburn LR, Chinoy H, Betteridge ZE, North J, Ollier WE, et al, for the Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 180714.
  • 26
    Rider LG, Lachenbruch PA, Monroe JB, Ravelli A, Cabalar I, Feldman BM, et al, for the IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the Myositis Damage Index. Arthritis Rheum 2009; 60: 342535.
  • 27
    Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 126878.
  • 28
    Oddis CV, Rider LG, Reed AM, Ruperto N, Brunner HI, Koneru B, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. Arthritis Rheum 2005; 52: 260715.
  • 29
    Mani RB. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 2004; 23: 30514.
  • 30
    Agarwal S, Kiely PD. Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis. Rheumatology (Oxford) 2006; 45: 8749.
  • 31
    Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti–signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50: 20915.
  • 32
    Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70: 36074.
  • 33
    Ruperto N, Ravelli A, Pistorio A, Ferrianni V, Calvo I, Ganser G, et al, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum 2008; 59: 413.